BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Employees - 16, CEO - William V. Williams FCPA,, Sector - Healthcare, Country - CA, Market Cap -

Altman ZScore(max is 10): -12.61, Piotroski Score(max is 10): 1, Working Capital: $10454565, Total Assets: $17001798, Retained Earnings: $-103664194, EBIT: -25679921, Total Liabilities: $5060645, Revenue: $0

- Current Price $ - Analyst Target Price $